Riboxx and CNBG Initiate a Collaboration
News Mar 06, 2013
Riboxx Pharmaceuticals GmbH (Riboxx) and China National Biotec Group Company Limited (CNBG) have announced that they have initiated a research collaboration to evaluate Riboxxim®, a TLR3 agonist from Riboxx, with an antigen of CNBG against one of the world’s deadliest infectious diseases.
During the term of the research collaboration, Riboxx will provide access to Riboxxim® to enable CNBG to perform an evaluation in conjunction with CNBG’s antigen against the disease target.
Dr. Jacques Rohayem, CEO of Riboxx said: “We are delighted to initiate this collaboration with CNBG, which is one of the leading developers of vaccines against serious infectious diseases. Our TLR3 agonist has the potential to increase the efficacy of the antigen and provide a safe but highly effective immune response against the disease.”
Xie Guilin, Vice President of CNBG said: “The collaboration with Riboxx is designed to evaluate the potential of Riboxxim as an effective adjuvant to enhance the performance of our antigen. This combination has the potential to deliver effective immunization against a deadly disease that is inadequately treated at present.”
Innate Immune Cells Reprogrammed to Fight TuberculosisNews
A cure has eluded scientists for more than a century but, now, a Montreal team of researchers may have discovered a new weapon to combat this global killer. The team is re-programing - or 'training' - immune cells to kill TB. These groundbreaking findings are published online today in the journal Cell.READ MORE
Antibiotic Micro-beads Fight Infection in Joint ReplacementsNews
More than 1 million people undergo total joint replacements each year, and nearly 10,000 will develop infections. To reduce this infection risk, an orthopedic surgeon has created small antibiotic beads that are implanted with the new joint to slowly release medicine for several weeks.READ MORE
Repeated Influenza Vaccination Effectively Prevents Severe Flu in Older AdultsNews
Repeated vaccination for influenza in older adults reduced the severity of the virus and reduced hospital admissions, found new research published in CMAJ.READ MORE